
The European Commission has launched today a public consultation inviting all interested parties to comment on the revision of the R&D and Specialization Block Exemption Regulations, known as the Horizontal Block Exemption Regulations, and accompanying Guidelines. Today’s consultation is part of the on-going review process initiated in September 2019 to ensure revised rules are in place when the current rules expire in December 2022.
The public consultation in the form of an online questionnaire seeks views on the different policy options and additional proposals for revision outlined in the Inception Impact Assessment. The public consultation forms part of the impact assessment phase of the review that seeks to address the issues raised during the evaluation phase and to assess the impact of the policy options proposed by the Commission.
The deadline for providing feedback is 5 October 2021. Following this, interested parties will have the possibility to provide their views on the draft revised rules that the Commission will publish for comments. The preceding evaluation phase showed that the rules on horizontal agreements between companies and the Horizontal Guidelines are useful tools for businesses. At the same time, the evaluation has identified several areas where the rules are not sufficiently adapted, in particular, in relation to digitization and the pursuit of sustainability goals
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas